This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer (beta)

    Based on guidelines from the American Society of Clinical Oncology.

    Strength
    Strong recommendation
    Moderate recommendation
    Weak recommendation
    Evidence
    High quality evidence
    Intermediate quality evidence
    Low quality evidence
    Insufficient evidence
    N/A

    Optimal Duration

    High Risk of Recurrence (T4 and/or N2)
    1. For patients with high-risk (T4 and/or N2) stage III resected colon cancer, adjuvant oxaliplatin-containing chemotherapy should be offered for a duration of 6 months.
    Low Risk of Recurrence (T1, T2, or T3 and N1)
    1. For patients with low-risk (T1, T2, or T3 and N1) stage III resected colon cancer, adjuvant oxaliplatin-containing chemotherapy may be offered for a duration of 3 months or 6 months after a discussion with the patient of the potential benefits and risks of harm associated with the options for treatment duration.
    Approach
    1. A shared decision-making approach should be used for duration of oxaliplatin-containing chemotherapy for patients with stage III resected colon cancer, taking into account a patient’s tumor characteristics, completeness of surgical resection, number of lymph nodes examined, comorbidities, functional status, performance status, values and preferences, age at diagnosis, life expectancy, potential years at risk for long-term sequalae of treatment, and including a discussion of the potential for benefit and risks of harm associated with treatment duration.
    What do the icons mean?  
    Research PaperLieu C, Kennedy EB, Bergsland E, et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(16):1436-1447.